New drug trial hopes to tame rare skin disease
NCT ID NCT06539507
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called BCX17725 in healthy volunteers and people with Netherton syndrome, a rare genetic skin condition. The study aims to check safety, how the drug moves through the body, and whether it can reduce skin redness and scaling. About 78 participants will take part across four parts, with the final part also looking at effectiveness over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BCX17725
What this could lead to
If successful, this could point toward a treatment that controls the severe skin symptoms of Netherton syndrome.
What could go wrong
This is a very early Phase 1 trial, so safety and effectiveness are not yet known. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dawes Fretzin Clinical Research Group, LLC
RECRUITINGIndianapolis, Indiana, 46250, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Erasmus Universitair Medisch Centrum (EMC)
RECRUITINGRotterdam, 3015 GD, Netherlands
-
Hôpital Saint-Louis
RECRUITINGParis, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Maastricht Universitair Medisch Centrum (MUMC+)
RECRUITINGMaastricht, 6229 HX, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern Dermatology CTU
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nucleus Network
COMPLETEDBrisbane, Queensland, 4006, Australia
-
Stanford University School of Medicine
NOT_YET_RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Therapeutics Clinical Research
RECRUITINGSan Diego, California, 92123, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Heidelberg
NOT_YET_RECRUITINGHeidelberg, 69120, Germany
-
Veracity Clinical Research
RECRUITINGBrisbane, Queensland, 4102, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Westmead Hospital - Department of Dermatology
RECRUITINGSydney, New South Wales, 2145, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale Center for Clinical Investigation
RECRUITINGNew Haven, Connecticut, 06519, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••